Global

A new report suggests that the Covid-19 vaccine being developed by Pfizer and BioNTech is showing positive results in current trials.

The company said it could move to the next phase of trials with 30,000 as early as later this month.

The trial gave 24 of its 45 participants two doses of the coronavirus vaccine, and all 24 produced antibodies.

An early trial of an experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE showed it’s safe and prompted patients to produce antibodies against the new virus.

Gilead Sciences is the frontrunner among six pharma companies, seeing a $15.7 billion gain in market value, helped by its trials of the antiviral medication Remdesivir.

By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.

However, the price was swiftly criticized.

CNBC's Meg Tirrell breaks down how Gilead decided on its pricing for its coronavirus drug remdesivir.

Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance.

Gilead CEO Daniel O'Day joins "Squawk Box" to discuss the price tag as well as ensuring patients have access to the drug and concerns surrounding the supply chain.

Researchers are looking at how to ensure equitable distribution of a COVID-19 vaccine for countries most vulnerable to the coronavirus outbreak.

The world is sitting on the edge of its seat, waiting for new Covid-19 vaccines and treatments.

In the race for a coronavirus vaccine governments around the world are throwing billions of dollars at pharma firms to be first to come up with a solution.

Approximately 200 COVID-19 vaccines are being actively developed.

The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest.